NOV Inc. designs, constructs, manufactures, and sells systems, components, and products for oil and gas drilling and production, and industrial and renewable energy sectors in the United States and internationally. It operates through two segments, Energy Equipment, and Energy Products and Services. The company provides solids control and waste management equipment and services, managed pressure drilling, drilling fluids, premium drillpipe, wired pipe, drilling optimization services, tubular inspection and coating services, instrumentation, downhole tools, and drill bits. It also offers equipment and technologies for hydraulic fracture stimulation, including downhole multistage fracturing tools, pressure pumping trucks, blenders, sanders, hydration and injection units, flowline, and manifolds; coiled tubing units, and wireline units and tools; connections and liner hangers; onshore production consists of composite pipe, surface transfer and progressive cavity pumps, and artificial lift systems; and offshore production, such as floating production systems and subsea production technologies, as well as manufactures industrial pumps and mixers. In addition, the company provides substructures, derricks, and masts; cranes; jacking systems; pipe lifting, racking, rotating, and assembly systems; mud pumps; pressure control equipment; drives and generators; rig instrumentation and control systems; mooring, anchor, and deck handling machinery; equipment components for offshore wind construction vessels; and pipelay and construction systems. Further, the company offers spare parts, repair, and rentals as well as comprehensive remote equipment monitoring, technical support, field service, and customer training. The company was formerly known as National Oilwell Varco, Inc. and changed its name to NOV Inc. in January 2021. NOV Inc. was founded in 1862 and is based in Houston, Texas.

NOV Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN – Research Report) and Novan (NOVN – Research Report...

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Novan (NOVN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novan (NOVN – Research Report) and Generation Bio (GBIO – Researc...

Analysts Conflicted on These Healthcare Names: Novan (NOVN) and Generation Bio (GBIO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novan (NOVN – Research Report) and Merus (MRUS – R...

Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Merus (MRUS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kyverna Therapeutics, Inc. (KYTX – Research Report) ...

Analysts Offer Insights on Healthcare Companies: Kyverna Therapeutics, Inc. (KYTX) and Novan (NOVN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novan (NOVN – Research Report) and Argenx Se (ARGX –...

Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Argenx Se (ARGX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sionna Therapeutics, Inc. (SION – Research Report) a...

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Novan (NOVN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Novan (NOVN – Research Report)...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Novan (NOVN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novan (NOVN – Research Report) and Thermo Fisher (TM...

Analysts’ Top Healthcare Picks: Novan (NOVN), Thermo Fisher (TMO)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk today and set a price target of DKK475.00. Papadakis covers the He...

Novo Nordisk (0QIU) Receives a Buy from Deutsche Bank

UBS analyst Matthew Weston maintained a Hold rating on Novo Nordisk today and set a price target of DKK295.00. According to TipRanks, Weston is a 4...

UBS Remains a Hold on Novo Nordisk (0QIU)

Novatti Group ( ($AU:NOV) ) has provided an update. Novatti Group Limited announced the quotation of 1,326,498 fully paid ordinary securities on th...

Novatti Group Expands Market Presence with New Securities Quotation

The obesity treatment space has been generating plenty of headlines – and sales – over the past few years. GLP-1 receptor agonists such as semaglut...

LLY and NOVO: Goldman Sachs Weighs In on the Top Obesity Stocks to Watch in 2026

Enovis ( ($ENOV) ) has provided an update. On December 8, 2025, Enovis Corporation amended its existing credit agreement to enhance its financial f...

Enovis Amends Credit Agreement for Financial Flexibility

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk today and set a price target of DKK352.00. Quigley covers the Healthcar...

Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk, with a price target of DKK295.00. Weston covers the H...

UBS Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Morgan Stanley analyst Thibault Boutherin upgraded Novartis AG to a Buy today and set a price target of CHF115.00. Boutherin covers the Healthcare ...

Morgan Stanley upgrades Novartis AG (NOVN) to a Buy

Bank of America Securities analyst Sachin Jain reiterated a Hold rating on Novo Nordisk yesterday and set a price target of DKK340.00. The company’...

Novo Nordisk (0QIU) Receives a Hold from Bank of America Securities

Novatti Group ( ($AU:NOV) ) just unveiled an announcement. Novatti Group Limited has announced a change in the interests of its director, Peter Paw...

Novatti Group Announces Director’s Change in Securities Interest

Novo Nordisk ( ($NVO) ) has risen by 8.32%. Read on to learn why. Novo Nordisk’s stock has seen an impressive 8.32% rise over the past week, driven...

Novo Nordisk’s Stock Surges Amid Drug Breakthrough

Novatti Group ( ($AU:NOV) ) has provided an update. Novatti Group Limited has announced the appointment of Christopher Ryan as a director, effectiv...

Novatti Group Appoints New Director with Significant Securities Interest

In a report released on November 25, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk, with a price target of DKK510.00. The...

Kepler Capital  Keeps Their Buy Rating on Novo Nordisk (0QIU)

Novatti Group ( ($AU:NOV) ) has provided an announcement. Novatti Group Limited announced the cessation of Killian Murphy as a director, effective ...

Novatti Group Announces Director Departure and Interest Notice

Novo Nordisk ( ($NVO) ) has shared an update. Novo Nordisk announced positive results from a phase 2 clinical trial of amycretin, a new treatment f...

Novo Nordisk Reports Positive Phase 2 Results for Amycretin in Type 2 Diabetes

Novatti Group ( ($AU:NOV) ) has issued an announcement. Novatti Group Limited announced its Annual General Meeting for 2025, emphasizing a strategi...

Novatti Group’s 2025 AGM: Strategic Pivot Towards Growth

Novatti Group ( ($AU:NOV) ) has provided an announcement. Novatti Group Limited has announced the appointment of two new Non-Executive Directors, C...

Novatti Group Strengthens Board with Strategic Appointments

An update from Novo Nordisk ( ($NVO) ) is now available. On November 24, 2025, Novo Nordisk announced the results of its evoke and evoke+ phase 3 t...

Novo Nordisk’s Alzheimer’s Trials Show No Significant Progress

Jefferies analyst Michael Leuchten maintained a Sell rating on Novo Nordisk today and set a price target of DKK290.00. According to TipRanks, Leuch...

Jefferies Remains a Sell on Novo Nordisk (0QIU)

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on November 21 and set a price target of CHF106.00. The company’s shares ...

Kepler Capital  Keeps Their Buy Rating on Novartis AG (NOVN)

Morgan Stanley analyst Thibault Boutherin maintained a Buy rating on Novartis AG yesterday. The company’s shares closed today at CHF100.42. Bouther...

Morgan Stanley Reaffirms Their Buy Rating on Novartis AG (NOVN)

Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG yesterday and set a price target of CHF108.00. Cespedes covers the Health...

Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)

Saudi Arabian Oil, also known as Aramco, signed new deals with a wide set of U.S. firms. The plan took shape at the U.S.-Saudi Investment Forum in ...

Aramco Strikes Up to $30 billion in U.S. Energy and LNG Deals at Washington Forum

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk, with a price target of DKK315.00. According to TipRan...

Berenberg Bank analyst Luisa Hector maintained a Hold rating on Novartis AG today and set a price target of CHF92.00. According to TipRanks, Hector...

Berenberg Bank Sticks to Its Hold Rating for Novartis AG (NOVN)

Novatti Group ( ($AU:NOV) ) has issued an announcement. Novatti Group Limited announced that its AUDD stablecoin has surpassed $1 billion in transa...

Novatti’s AUDD Stablecoin Surpasses $1 Billion in Stellar Blockchain Transactions

The latest announcement is out from Novo Nordisk ( ($NVO) ). On November 17, 2025, Novo Nordisk announced transactions involving its shares by boar...

Novo Nordisk Announces Insider Share Transactions

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Novanta (NOVT – Research Report) and Applied Digital...

Analysts Offer Insights on Technology Companies: Novanta (NOVT) and Applied Digital Corporation (APLD)

An update from Novamarine S.P.A. ( ($IT:NOVA) ) is now available. Novamarine S.p.A. has approved a capital increase and a shareholder loan for its ...

Novamarine Boosts Tornado Boat Production with Capital Increase and Loan

In a report released on November 14, David Evans from Kepler Capital maintained a Buy rating on Novartis AG, with a price target of CHF106.00. The ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NOV	$16.24	-0.92%	4.05M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NOV	$16.24	-0.9%	4.05M
3
4
5
6

NOV

NOV

Get NOV Inc. Data in Excel

Get NOV Inc. Data in Excel